A 38-week, double-blind study of a long-acting injectable, second-generation antipsychotic medication compared to its oral formulation as a maintenance treatment for schizophrenia

In this outpatient study, patients would be stabilized on an FDA-approved second-generation antipsychotic medication. After achieving psychiatric stability for eight weeks, patients would be randomly assigned to continue taking the oral medication or to receive the long-acting injection (administered monthly). All study procedures, including study medication and regular checkups and mental health evaluations, will be covered by the sponsor. Patients or their insurance would not be charged.

We will be enrolling about 10 patients at Rush through next summer. Please contact us for more information.

You may be eligible to participate in this study if you:

• Are 18-60 years of age
• Have been diagnosed with schizophrenia
• Are medically stable

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.